52results about How to "Lower drug concentration" patented technology

The invention relates to anti-cancer drug slow release agent containing epothilone, which consists of slow release microspheres and solvent, wherein the slow release microspheres comprise anti-cancer effective components and slow release accessories; and the solvent is special solvent containing suspending agent. The anti-cancer effective components are combinations of epothilone, epothilone derivative, epothilone B, epothilone D and anticancer drugs selected from phosphoinositide 3-kinase inhibitor, pyrimidine analog and/or DNA repairase inhibitor, and the like; the slow release accessories are biocompatible high molecules such as polylactic acid and copolymer thereof, polyethylene glycol, terminal carboxyl polylactic acid copolymer, di-fatty acid and sebacic acid copolymer, poly (erucic acid dimmer-sebacic acid), poly (fumaric acid-sebacic acid), polifeprosan, polylactic acid, and the like; and the suspending agent is selected from sodium carboxymethyl cellulose and the like when the viscosity of the suspending agent is 100 to 3,000cp (at a temperature of between 20 and 30 DEG C). The anti-cancer effective components and the slow release microspheres can also be made into slow release implant agents, can effectively inhibit tumor growth through injection or placement and energy removal in tumor or tumor periphery, and can also remarkably enhance curative effect of non-operative treatment such as chemicotherapy and the like.

The invention relates to a nerve growth factor sponginum and a preparation method thereof, belonging to the technical field of medicine. The sponginum comprises nerve growth factor with weight percent content being 0.01-2% and collagen sponge or gelatin sponge matrix, the nerve growth factor is fixed on the collagen sponge or gelatin sponge matrix in a crosslinking way by an aldehydes crosslinker. The sponginum can cause the nerve growth factor to be released to the nerve pathology or wound tissue partial position continuously for a long time in effective dose, and play a role in effectively curing nerve tissue damage.

The invention provides a medicine composite used for embolotherapy and acesodyne and a preparation method thereof. The medicine composite comprises a biocompatibility macromolecular compound containing hydroxy, a monomer containing unsaturated double bond and anion group, a polymer, and local anesthetic containing amino group, wherein the polymer is generated through a polymerization reaction of an optional vinyl monomer and the polymerization reaction is initiated by free radicals, and the local anesthetic is combined to an anion group of the generated polymer. In the invention, lidocaine hydrochloride is combined to a polymer carrier; which can give full play to the acesodyne effect of the local anesthetic in the embolotherapy; the anion part of the polymer can properly combine with the local anesthetic containing the amino group, which can both realize higher medicine loading capacity and enable the medicine in an emboliaztion agent to be exchanged by cations in vivo and then slowly released. Moreover, the polymer emboliaztion carrier has simple technology, low cost, and suitability for large scale industrial production.

An oil-in-water zedoary oil-fat emulsion for treating viral disease and cancer by injecting or oral taking is proportionally prepared from zedoary oil, soybean oil, lecithin, glycerin, oleic acid and the water for injection through high-speed stirring or ultrasonic oscillating, and high-pressure homogenizing. Its advantages are low by-effect and high curative effect.

The invention relates to a preparation method of a bracket with a drug temperature-sensitive controlled-release function. By the preparation method of the bracket, the coating with the drug temperature-sensitive controlled-release function is applied on the surface of the bracket in the modes of spin coating, dip coating or spray coating. The invention also provides a preparation method of the coating with the drug temperature-sensitive controlled-release function. The preparation method of the invention is simple and has strong operability. The coating with the drug temperature-sensitive controlled-release function prepared by the method of the invention has good temperature sensibility and drug controlled release function. The bracket with the drug temperature-sensitive controlled-release function prepared by the method can make histocyte drugs around the bracket have high concentration, and the drugs in blood have low concentration. With the existing drug eluting bracket, the histocyte drugs around the bracket have low concentration, and the drugs in the blood have high concentration. Compared with the existing drug eluting bracket, the bracket with the drug temperature-sensitive controlled-release function prepared by the method of the invention has significant advantages.

The invention discloses a pingyangmycin polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) temperature-sensitive slow-release gel, as well as a preparation method and the application of the gel. The Pingyangmycin PEG-PCL-PEG temperature-sensitive slow-release gel mainly consists of two parts comprising PEG (polyethylene glycol)-PCL (polycaprolactone)-PEG (polyethylene glycol) co-polymer and Pingyangmycin, is liquid at room temperature, and is solid gel under the in vivo 37 DEG C condition; the gel system has significant slow-release effect, thereby having functions in prolonging the half-life period and the acting time of the Pingyangmycin, reducing drug concentration in plasma, and reducing systemic toxic and side effects. The gel can be formed in situ after the medicine is injected in a high-flow-speed vessel, and then location embolism is realized, and so as to realize the, and muscularization and closing of muscle is caused, so that the sclerotherapy and the interventional therapy are combined effectively, the gel has excellent biocompatibility and degradability, is beneficial for treating hemangiomas, vascular malformations and cancers, particularly, a new selection is provided to the treatment of the vein malformation and partial malformation of cancers.

The invention relates to a bracket with a drug temperature-sensitive controlled-release function, which consists of a supporting bracket and a drug-carrying coating which covers the surface of the bracket, wherein the drug-carrying coating is formed by applying the coating with the drug temperature-sensitive controlled-release function on the surface of the bracket in the modes of spin coating, dip coating or spray coating. The invention also provides a coating with the drug temperature-sensitive controlled-release function and the application thereof. The coating with the drug temperature-sensitive controlled-release function has good temperature sensibility and drug controlled release function, can be evenly applied on the surface of bracket material. The drug-carrying bracket can effectively kill cancer cells and restrain the proliferation of nude mouse cancer transplantation tumor.

The present document describes an enzyme formulation comprising an enzyme mixture comprising from about 5% to about 45% (wt/wt) of a fungal protease enzyme; and from about 1.5% to about 50% (wt/wt) of at least one polysaccharide digesting enzyme; in combination with an acceptable pharmaceutical carrier. The present document also describes the use of the formulation of the present invention for the prevention or treatment of digestive disorder.

The invention discloses a compound docetaxel ester microsphere injection and a preparation method thereof, belonging to the technical field of medicines. The compound docetaxel ester microsphere injection is characterized by being prepared from the following raw materials in weight parts: 0.5 to 5 parts of docetaxel, 30-150 parts of Brucea javanica oil, 30-150 parts of middle-chain triglyceride, 10-30 parts of lecithin, 10-60 parts of polyethylene glycol surface active agents, 20-35 parts of glycerine and 700-950 parts of sterilized water for injection. The compound docetaxel ester microsphere injection of the invention is oil in water type microsphere preparation. The docetaxel as a main drug is coated in the Brucea javanica and middle-chain triglyceride compound oil phase of the oil in water type microsphere. The microsphere has a smaller grain diameter (which is lower than 100nm), and the preparation has better stability. The compound oil phase compositions play a cooperative anticancer role, and reduce the stimulation reaction of the injection and the side reactions such as hemolysis, allergy and the like. The invention has targeting function and increases the medicine effect.

The present invention belongs to the field of biomedicine, and particularly relates to an antitumor slow-release implantation agent, which comprises 10-hydroxycamptothecin, a degradable polymer and metal magnesium, and is obtained by a solution spraying or hot-melting extrusion process. According to the present invention, after the implantation agent is subjected to the surgical implantation, the slow release of the10-hydroxycamptothecin can be achieved, and compared with the traditional administration mode, the administration mode of the present invention has the following characteristics that the drug systemic toxicity can be substantially reduced in the premise of the effective maintenance of the local drug concentration of the tumor; the metal magnesium in the implantation agent can react with water in the body environment to generate magnesium hydroxide, such that the environment around the tumor can be adjusted to achieve the alkaline state so as to inhibit the tumor cell growth; and the implantation agent can be used alone or can be combined with other treatment methods to provide the treatment or tumor recurrence prevention effect.

The invention discloses asarin lipid nanospheres and a method for preparing the same, and belongs to the technical field of medicaments. The asarin lipid nanospheres are prepared by the homogenization of the following raw materials in part by weight: 0.2 to 1.0 part of asarin, 5 to 15 parts of medium chain oil, soybean oil or the mixture of the medium chain oil and the soybean oil, 0.5 to 5 parts of lecithin, 1 to 30 parts of polyethylene glycol-12-methyl hydroxystearate, 1 to 4 parts of glycerol and 40 to 100 parts of water for injection. The preparation method comprises the following steps of: adding the oil phase into the aqueous phase, stirring the mixed solution to obtain the coarse product, adjusting the pH value, and repeatedly homogenizing the coarse product by a homogenizer to obtain the finished product. The average grain size of the lipid nanospheres is less than 100nm; compared with asarin injections and big-grain size emulsions which are sold on markets, the asarin lipid nanospheres obviously improve the targeting property in the lung, obviously reduce the distribution in the hepatic tissue, lower the potential hepatic toxicity and improve the drug efficacy.

The invention discloses an elemene cabazitaxel compound flexible emulsion and a preparation method thereof. The emulsion is prepared from the following raw materials: 0.1-2g/100mL elemene, 0.05-0.3 g/100mL cabazitaxel, 2-20g/100mL oil, 1-3g/100mL phospholipid, 0.3-4g/100mL polyethylene glycol derivative, 2-10g/mL osmotic pressure regulator and the balance of water. The preparation method comprisesthe following steps: (1) melting the oil, the phospholipid, the polyethylene glycol derivative, the elemene and the cabazitaxel to obtain an oil phase; (2) mixing the osmotic pressure regulator withthe water to obtain a water phase; and (3) adding the oil phase into the water phase, performing shearing and homogenizing under high pressure, adjusting the pH value, and performing sub-packaging. The elemene and the cabazitaxel are encapsulated in the flexible emulsion at the same time, so that the pharmacokinetic behavior of medicines is remarkably improved, the anti-drug-resistance effect of the medicines and the permeability of the medicines entering cells are improved, the curative effect is enhanced, and the safety of the medicines is remarkably improved.

The invention discloses a sustained-release nano-gel by aerosol targeted drug delivery for treating respiratory system diseases. Sodium alginate high-molecular polymer is used as a vector material toconstruct a zinc alginate nano-gel drug delivery system to serve as a drug release storage cavern. Icariin-zinc alginate nano-gel is delivered to the lung in a targeted manner by adopting a drug delivery mode of ultrasonic aerosol inhalation, so that the liver first-pass effect of drugs can be avoided, response is rapid, and clinical drug delivery characteristics are accorded. The icariin-zinc alginate nano-gel can be directly and quickly distributed to the whole lung after ultrasonic aerosol inhalation, and can be adhered to the lung surface to constantly and stably release the icariin, so that the bioavailability of drugs can be improved, and the effect of treating respiratory system diseases can be achieved. Therefore, a proper and efficient novel preparation is provided to icariin treated respiratory system diseases, and targeted drug delivery can be performed through ultrasonic aerosol inhalation, and the application range of the sustained-release nano-gel can be enlarged.

Disclosed is a compound anticancer slow release injection of mesenchyme hydrolytic reagent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer active ingredient is the combination of mesenchyme hydrolytic reagent selected from collagenase, hyaluronidase, lysozyme, relaxin, plaxmin, gefinitib and erlotinib with anti-cancer drugs selected from anti-cancer antibiotic drugs and/or antimetabolites. The slow release auxiliary materials are selected from polylactic acid and its copolymer, di-aliphatic acid and sebacylic acid copolymer, poly(erucic aciddipolymer-sebacylic acid), poly(fumaric acid-sebacylic acid), Polifeprosan, EVAc or their combination, the viscosity of the suspension adjuvant is 80-3000cp. The slow release microspheres can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a release period of about 40 days. The slow release injection and slow release implanting agent can be used independently for effectively suppressing tumor accretion, or used in combination with non-operative methods such as chemotherapy and/or radiotheraphy with the function of improving their treatment effects.

The invention relates to a brain-targeted tanshinone oral oil-in-oil type microemulsion preparation, which is suitable for preventing and treating cerebrovascular diseases and central nervous system diseases. The preparation of the present invention utilizes the combination of the characteristics of nanoparticles and the increase of the fat solubility of the preparation to promote the penetration of the drug through the blood-brain barrier, improve the selective enrichment of the drug in the brain, provide a higher concentration of the drug in the brain, and significantly increase the concentration of the drug in the brain. residence time, thereby improving the prevention and treatment of corresponding brain diseases.

The invention discloses application of fullerol and a composition thereof in preparing antithrombotic drugs, and relates to the technical field of medicine. Specifically, the application of the fullerol C60(OH)X in preparing drugs for dissolving thrombus and/or inhibiting thrombosis is studied, wherein X is larger than or equal to 10 and less than 40, and the drugs comprise the fullerol and/or meso-porous silicon and/or cytomembrane; further more, it is found that the components of a composition used for inhibiting and/or dissolving the thrombus mainly comprise the fullerol, the meso-porous silicon, erythrocyte membrane and platelet membrane, and can also comprise a solvent and/or a pharmaceutically acceptable carrier. In the application of the composition in preparing the antithrombotic drugs, the drugs can be prepared into various dosage forms, and the dosage amounts corresponding to the dosage forms are 0.4 mg/kg/day in terms of the fullerol. It is found through studies that the fullerol has obvious thrombolytic and antithrombotic effects, the targeting and enrichment of the thrombus can be enhanced by loading biological membranes with fullerol nanomedicine, and a good thrombolytic effect is achieved.

The invention provides an abamectin transdermal solution and a preparation method thereof. The abamectin transdermal solution comprises abamectin, azone, sec-butyl acetate, ethyl acetate, N, N-dimethylacetamide, glycerol methylal and methyl pyrrolidone. The azone and the methyl pyrrolidone are used as composite penetrating agents, and sucrose acetate isobutyrate and benzyl alcohol are used as sustained-release transdermal enhancers, so that the treatment effect is prolonged under the action of the sustained-release transdermal enhancers while the rapid penetration treatment of the abamectin transdermal solution is ensured. The sec-butyl acetate, the ethyl acetate, the N, N-dimethylacetamide and the glycerol methylal are used as a mixed solvent, so that the stability of veterinary drugs can be improved, the viscosity can be reduced, drug residues and toxic and side effects can be reduced, and a synergistic effect can be achieved.

The invention discloses a recombinant human epidermal growth factor acoustic sensitive nano lipidosome and a preparation method thereof, and belongs to the technical field of medicine preparations. The preparation method comprises the following steps: (1) preparing oleic acid modified Fe3O4 magnetic nanoparticles; (2) preparing recombinant human epidermal growth factor acoustic sensitive nano lipidosome. The recombinant human epidermal growth factor acoustic sensitive nano lipidosome is prepared by using the preparation method. The recombinant human epidermal growth factor acoustic sensitive nano lipidosome has the advantages that oleic acid modified Fe3O4 magnetic nanoparticles are good in dispersibility and not liable to aggregate; magnetic nanoparticles are added when a membrane is laid in the preparation process, the modified magnetic nanoparticles are positioned in hydrophobic lipid bilayers, the mole ratio of lipid to cholesterol is about 2.4, and the phase-change temperature is relatively reduced; the nano lipidosome not only has magnetic steering properties, but also has acoustic-sensitive properties, the rhEGF bioavailability is improved, and furthermore the targeting treatment function of rhEGF is improved.